Gland Pharma Ltd Share Price (GLAND)

Gland Pharma's ROE is Low, but Analysts Expect Earnings to Accelerate - 18 Apr, 2024

Gland Pharma's low ROE and lack of regular dividends raise questions about its use of profits. However, industry analysts predict an acceleration in earnings.

Gland Pharma Sees Business Recovery; Promoters Sell Stake - 10 Apr, 2024

Gland Pharma reports a strong business recovery in FY23 due to new product launches, market share gains, and drug shortages in the US. Meanwhile, former promoters and Lakumi Trust sell a combined 4.88% stake in the company.

Gland Pharma Shares Sold Through Block Deals - 09 Apr, 2024

Multiple entities have sold significant stakes in Gland Pharma through block deals and open market transactions, totaling over Rs 3,000 crore. The official buyers and sellers of the block deals are not yet known.

Gland Pharma Receives USFDA Approval; Equity Sale Announced - 08 Apr, 2024

Gland Pharma has received USFDA approval for its anti-cancer medication, Eribulin Mesylate Injection, and Nicomac Machinery and RP Advisory Services plan to sell 4.4% of the company's equity for ₹1,400 crore.

Gland Pharma Receives FDA Approval for New Product - 06 Apr, 2024

Gland Pharma has received approval from the USFDA for its Eribulin Mesylate Injection product. The company expects to launch this product in the near term through its marketing partner. The product has US sales of approximately USD 92 million for twelve months ending in February 2024.

Gland Pharma Expected to Clock 16% Sales CAGR - 21 Mar, 2024

Gland Pharma is expected to see a 16% compound annual growth rate in sales to Rs 33 billion. Motilal Oswal has reiterated its buy view on the stock with a target of Rs 2240 per share, expecting an 11% CAGR in sales over FY24-26. The brokerage firm also values Gland at 27x12M forward earnings and expects a 20% earnings CAGR over FY24-26.